MDR1/P-GLYCOPROTEIN, TOPOISOMERASE, AND GLUTATHIONE-S-TRANSFERASE-PI GENE-EXPRESSION IN PRIMARY AND RELAPSED STATE ADULT AND CHILDHOOD LEUKEMIAS

被引:113
作者
GEKELER, V
FRESE, G
NOLLER, A
HANDGRETINGER, R
WILISCH, A
SCHMIDT, H
MULLER, CP
DOPFER, R
KLINGEBIEL, T
DIDDENS, H
PROBST, H
NIETHAMMER, D
机构
[1] MED LASERZENTRUM, W-2400 LUBECK, GERMANY
[2] UNIV TUBINGEN, KINDERKLIN, W-7400 TUBINGEN 1, GERMANY
[3] UNIV TUBINGEN, MED KLIN, W-7400 TUBINGEN 1, GERMANY
关键词
D O I
10.1038/bjc.1992.304
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In a variety of adult and childhood leukaemia cell samples collected at different states of the disease, we analysed in a series of sequentially performed slot-blot or Northern-blot hybridisation experiments the expression of genes possibly involved in multiple drug resistance (MDR) (mdr1/P-glycoprotein, DNA topoisomerase II, glutathione-S-transferase-pi), and the expression of the DNA topoisomerase I and histone 3.1 genes. Occasionally, P-glycoprotein gene expression was additionally examined by indirect immunocytofluorescence using the monoclonal antibody C219. No significant difference in mdr1/P-glycoprotein mRNA levels between primary and relapsed state acute lymphocytic leukaemias (ALL) was seen on average. Second or third relapses, however, showed a distinct tendency to an elevated expression of this multidrug transporter gene (up to 10-fold) in part well beyond the value seen in the moderately cross-resistant T-lymphoblastoid CCRF-CEM subline CCRF VCR 100. Increased mdr1/P-glycoprotein mRNA levels were also found in relapsed state acute myelogeneous leukaemias (AML), and in chronic lymphocytic leukaemias (CLL) treated with chlorambucil and/or prednisone for several years. Topoisomerase I and topoisomerase II mRNA levels were found to be very variable. Whereas in all but one case of CLL topoisomerase II mRNA was not detected by slot-blot hybridisations, strong topoisomerase I and topoisomerase II gene expression levels, frequently exceeding the levels monitored in the CCRF-CEM cell line, were seen in many cell samples of acute leukaemia. If topoisomerase II mRNA was undetectable, expression of topoisomerase I was clearly visible throughout. These observations might be valuable considering the possible treatment with specific topoisomerase I or topoisomerase II inhibitors. Significant positive correlations were found (i) for topoisomerase I and histone 3.1 gene expression levels in general (P < 0.001), and (ii) in the CLL samples additionally for the expression levels of the mdr1 gene, and the histone 3.1, topoisomerase I, and glutathione-S-transferase pi-genes, respectively.
引用
收藏
页码:507 / 517
页数:11
相关论文
共 60 条
  • [1] THE GENE ENCODING MULTIDRUG RESISTANCE IS INDUCED AND EXPRESSED AT HIGH-LEVELS DURING PREGNANCY IN THE SECRETORY EPITHELIUM OF THE UTERUS
    ARCECI, RJ
    CROOP, JM
    HORWITZ, SB
    HOUSMAN, D
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (12) : 4350 - 4354
  • [2] BATIST G, 1986, J BIOL CHEM, V261, P5544
  • [3] COINDUCTION OF MDR-1 MULTIDRUG-RESISTANCE AND CYTOCHROME-P-450 GENES IN RAT-LIVER BY XENOBIOTICS
    BURT, RK
    THORGEIRSSON, SS
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1988, 80 (17) : 1383 - 1386
  • [4] CHEN AY, 1991, CANCER RES, V51, P6039
  • [5] INTERNAL DUPLICATION AND HOMOLOGY WITH BACTERIAL TRANSPORT PROTEINS IN THE MDR1 (P-GLYCOPROTEIN) GENE FROM MULTIDRUG-RESISTANT HUMAN-CELLS
    CHEN, CJ
    CHIN, JE
    UEDA, K
    CLARK, DP
    PASTAN, I
    GOTTESMAN, MM
    RONINSON, IB
    [J]. CELL, 1986, 47 (03) : 381 - 389
  • [6] ISOLATION OF BIOLOGICALLY-ACTIVE RIBONUCLEIC-ACID FROM SOURCES ENRICHED IN RIBONUCLEASE
    CHIRGWIN, JM
    PRZYBYLA, AE
    MACDONALD, RJ
    RUTTER, WJ
    [J]. BIOCHEMISTRY, 1979, 18 (24) : 5294 - 5299
  • [7] DRUG-RESISTANCE IN MULTIPLE-MYELOMA AND NON-HODGKINS LYMPHOMA - DETECTION OF P-GLYCOPROTEIN AND POTENTIAL CIRCUMVENTION BY ADDITION OF VERAPAMIL TO CHEMOTHERAPY
    DALTON, WS
    GROGAN, TM
    MELTZER, PS
    SCHEPER, RJ
    DURIE, BGM
    TAYLOR, CW
    MILLER, TP
    SALMON, SE
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (04) : 415 - 424
  • [8] DAVIES SM, 1988, J BIOL CHEM, V263, P17724
  • [9] DEFFIE AM, 1988, CANCER RES, V48, P3595
  • [10] DEJONG S, 1990, CANCER RES, V50, P304